UBS O'Connor’s Blueprint Medicines BPMC Stock Holding History

UBS O'Connor’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,000	Closed	-$30.8K	–	384
2025 Q1	$30.8K	Buy	+10,000	New	+$976K	﹤0.01%	296
2024 Q3	–	Sell	-20,000	Closed	-$51K	–	515
2024 Q2	$51K	Buy	+20,000	New	+$2M	﹤0.01%	447

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS O'Connor's BPMC Position: Q3 2025 in Review

UBS O'Connor sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,713,587 shares — an estimated $220M sold.

UBS O'Connor first reported a position in BPMC in Q1 2022 and held it in 13 quarters. The position peaked at $220M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

UBS O'Connor reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 1,713,587 Blueprint Medicines shares in Q3 2025, an estimated $220M.
UBS O'Connor first reported a position in Blueprint Medicines in Q1 2022 and held it in 13 quarters.
UBS O'Connor's Blueprint Medicines position peaked at $220M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.